Merck & Co., Inc. is a health care company ... animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

AIDDISON also encompasses SA-space, a synthetically accessible chemical space of approximately 25 billion virtual compounds built on the Sigma-Aldrich catalogue of molecules that are readily ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

The Merck product is licensed in both the European Union and the United States; the J&J vaccine is licensed in the European Union. Meakin and her co-authors calculated the vaccine effectiveness ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Merck's product development team lead for the newly cleared vaccine, told CNBC in an interview. "Those are things that have a ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

This marks Keytruda's first approval for the given indication. Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.